🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to researchers.

A Global Health Concern

The sexually transmitted infection are escalating worldwide, with estimates suggesting more than 82 million infections each year. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices presently on offer.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Clearance

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Results and Global Access

As per findings released by a major medical journal, zoliflodacin eradicated the vast majority of cases of the STI. This establishes an equal footing with the current standard treatment, which involves two antibiotics. The study enrolled over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have shared positive views. The availability of a one-pill regimen such as this is described as a "game-changer" for gonorrhoea control. This is considered essential to alleviate the strain of the illness for people and to stop the proliferation of untreatable gonorrhoea globally.